Inhibition of bone metastasis from breast carcinoma by rosmarinic acid

Planta Medica

Volumn 76, Issue 10, 2010, Pages 956-962

  Xu, Yichun ^a   Jiang, Zijing ^a   Ji, Guang ^b   Liu, Jianwen ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

bone metastasis; breast carcinoma; Lamiaceae; Prunella vulgaris L.; rosmarinic acid

Indexed keywords

ALKALINE PHOSPHATASE; COLONY STIMULATING FACTOR 1; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PRUNELLA VULGARIS EXTRACT; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROSMARINIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE MARROW CELL; BONE METASTASIS; BREAST CARCINOMA; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; METASTASIS INHIBITION; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BONE AND BONES; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CINNAMATES; DEPSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-8; MICE; NF-KAPPA B; OSTEOPROTEGERIN; PHYTOTHERAPY; PLANT EXTRACTS; PRUNELLA; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS;

LAMIACEAE; MURINAE; PRUNELLA VULGARIS;

EID: 77954870609     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1240893     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin 2007 57 43-66
2. Lipton A, Demers L, Daniloff Y. Increased urinary excretion of pyridinium crosslinks in cancer patients. Clin Chem 1993 39 614-618
3. Mundy G R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002 2 584-593
4. Clines G A., Guise T A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005 12 549-583
5. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin 2006 56 106-130
6. Body J J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003 97 859-865
7. Ma P L., Zhao P R., Tian A Q. The effect of Prunella vulgaris L. on Eca109 cells. J Basic Clin Oncol 2006 19 199-200
8. Qiao S, Li W, Subouchi R. Rosmarinic acid inhibits the formation of reactive oxygen and nitrogen species in RAW264.7 macrophages. Free Radic Res 2005 39 995-1003
9. Youn J, Lee K H., Won J. Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis. J Rheumatol 2003 30 1203-1207
10. Parnham M J., Kesselring K. Rosmarinic acid. Drugs Future 1985 10 756-757
11. Wang Z J., Zhao Y Y., Wang F. Depsides from Prunella vulgaris. Chin Chem Lett 2000 11 997-1001
12. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003 83 337-376
13. Hale L V., Ma Y F., Santerre R F. Semi-quantitative fluorescence analysis of calcein binding as a measurement of in vitro mineralization. Calcif Tissue Int 2000 67 80-84
14. Zhang J, Shen Y L., Liu J W. Antimetastatic effect of RA through inhibition of tumor invasion. Biochem Pharmacol 2005 69 407-414
15. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005 328 679-687
16. Hofbauer L C., Neubauer A, Heufelder A E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001 92 460-470
17. Kong Y Y., Yoshida H, Sarosi I. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 315-323
18. Hsu H, Lacey D L., Dunstan C R. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999 96 3540-3545
19. Nakagawa N, Kinosaki M, Yamaguchi K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998 253 395-400
20. Lacey D L., Timms E, Tan H L. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 165-176
21. Morony S, Capparelli C, Sarosi I. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001 61 4432-4436
22. Théoleyre S, Wittrant Y, Tat S K. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004 15 457-475
23. Simonet W S., Lacey D L., Dunstan C R. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319
24. Williams G T., Smith C A., Spooncer E. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990 343 76-79
25. Guise T A., Yin J J., Taylor S D. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996 98 1544-1549
26. Chirgwin J M., Guise T A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000 10 159-178
27. Chirgwin J M., Mohammad K S., Guise T A. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004 4 308-318
28. Yoshimura T, Matsushima K, Tanaka S. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987 84 9233-9237
29. Sozzani S, Locati M, Allavena P. Chemokines: a superfamily of chemotactic cytokines. Int J Clin Lab Res 1996 26 69-82
30. Bendre M S., Gaddy-Kurten D, Mon-Foote T. Expression of interleukin-8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002 62 5571-5579
31. Bendre M S., Margulies A G., Walser B. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-B ligand pathway. Cancer Res 2005 65 11001-11009
32. Benoy I H., Salgado R, Van Dam P. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004 10 7157-7162
33. Bendre M S., Montague D C., Peery T. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003 33 28-37
34. Thudi N K., Martin C K., Nadella M V. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Prostate 2008 68 1116-1125